LEO Pharma Submitted NDA Taclonex Scalp Gel To FDA

Taclonex Scalp Gel

LEO Pharma has submitted a New Drug Application for Taclonex Scalp gel to the U.S. Food and Drug Administration.

Taclonex Scalp gel is a topical gel for the treatment of scalp psoriasis vulgaris in adults. Taclonex Scalp gel contains the same active ingredients as Taclonex ointment (a combination of calcipotriene 0.005% and betamethasone dipropionate 0.064%).

More than 4.5 million adults in the United States have been diagnosed with psoriasis, and approximately 150,000 new cases are diagnosed each year. According to the National Psoriasis Foundation, at least half of all people diagnosed with psoriasis have it on their scalp.

Psoriasis is a chronic, inflammatory skin disease for which there is no cure. In plaque psoriasis (psoriasis vulgaris), the most common type, patches of skin called "lesions" become inflamed and are covered by silvery white scale. A non-contagious disorder, psoriasis can occur on any part of the body, and can significantly alter a sufferer's life both physically and mentally, including the ability to work, play and interact with others.

Warner Chilcott is LEO Pharma's exclusive licensee of Taclonex Scalp gel, Taclonex ointment and Dovonex in the United States.

Warner Chilcott Warner Chilcott is a leading specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription products in the women's healthcare and dermatology therapeutic categories in the United States.